124 related articles for article (PubMed ID: 11259100)
1. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.
Griggs J; Hesketh R; Smith GA; Brindle KM; Metcalfe JC; Thomas GA; Williams ED
Br J Cancer; 2001 Mar; 84(6):832-5. PubMed ID: 11259100
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.
Griggs J; Skepper JN; Smith GA; Brindle KM; Metcalfe JC; Hesketh R
Am J Pathol; 2002 Mar; 160(3):1097-103. PubMed ID: 11891206
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.
Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC
Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ
Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
8. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.
Parkins CS; Holder AL; Hill SA; Chaplin DJ; Tozer GM
Br J Cancer; 2000 Sep; 83(6):811-6. PubMed ID: 10952787
[TBL] [Abstract][Full Text] [Related]
9. Potent anti-metastatic activity of combretastatin-A4.
Griggs J; Brindle KM; Metcalfe JC; Hill SA; Smith GA; Beauregard DA; Hesketh R
Int J Oncol; 2001 Oct; 19(4):821-5. PubMed ID: 11562761
[TBL] [Abstract][Full Text] [Related]
10. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ
Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969
[TBL] [Abstract][Full Text] [Related]
12. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
Brooks AC; Kanthou C; Cook IH; Tozer GM; Barber PR; Vojnovic B; Nash GB; Parkins CS
Anticancer Res; 2003; 23(4):3199-206. PubMed ID: 12926054
[TBL] [Abstract][Full Text] [Related]
13. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-vascular therapy with texture analysis.
Chen G; Jespersen S; Pedersen M; Pang Q; Horsman MR; Stødkilde Jørgensen H
Anticancer Res; 2005; 25(5):3399-405. PubMed ID: 16101155
[TBL] [Abstract][Full Text] [Related]
15. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
[TBL] [Abstract][Full Text] [Related]
16. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
17. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.
Vitale I; Antoccia A; Cenciarelli C; Crateri P; Meschini S; Arancia G; Pisano C; Tanzarella C
Apoptosis; 2007 Jan; 12(1):155-66. PubMed ID: 17143747
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.
Grosios K; Holwell SE; McGown AT; Pettit GR; Bibby MC
Br J Cancer; 1999 Dec; 81(8):1318-27. PubMed ID: 10604728
[TBL] [Abstract][Full Text] [Related]
20. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile.
McGown AT; Fox BW
Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
